1219805-99-8
Chemical Structure
Doxofylline-d6
- CAS No.: 1219805-99-8
- Formula:C11H8D6N4O4
- Molecular Weight:272.29
IUPAC Name: 7-((1,3-dioxolan-2-yl)methyl)-1,3-bis(methyl-d3)-3,7-dihydro-1H-purine-2,6-dione
InChIKey: HWXIGFIVGWUZAO-WFGJKAKNSA-N
SMILES: O=C1C2=C(N=CN2CC3OCCO3)N(C([2H])([2H])[2H])C(N1C([2H])([2H])[2H])=O
Biological Activity: Doxofylline-d6 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Doxofylline-d6 | 99.61% | Doxofylline-d6 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxofylline (Standard) | ≥98% | Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxofylline-d4 | Doxofylline-d4 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxofylline | 99.97% | Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||